TY - JOUR
T1 - Development of cardiovascular risk factors in women with a BRCA1/2 pathogenic variant within five years after tubo-ovarian cancer risk reduction in the TUBA study
AU - Gootzen, Tamar A.
AU - van Gelder, Marleen M.H.J.
AU - Hermens, Rosella P.M.G.
AU - van Bommel, Majke H.D.
AU - Apperloo, Mirjam J.A.
AU - Arts-de Jong, Marieke
AU - Zanten, Monique M.A.Brood van
AU - Coppus, Sjors F.P.J.
AU - Custers, Jose
AU - van Doorn, Helena C.
AU - Gaarenstroom, Katja N.
AU - Harmsen, Marline G.
AU - Knippenberg, Marjan
AU - van Lonkhuijzen, Luc R.C.W.
AU - Piek, Jurgen M.J.
AU - Simons, Michiel
AU - Slangen, Brigitte F.M.
AU - Tros, Rachel
AU - Vos, M. Caroline
AU - Yigit, Refika
AU - Zweemer, Ronald P.
AU - Hoogerbrugge, Nicoline
AU - Kets, C. Marleen
AU - Maas, Angela H.E.M.
AU - Steenbeek, Miranda P.
AU - de Hullu, Joanne A.
N1 - Publisher Copyright:
© 2026 The Author(s)
PY - 2026/4
Y1 - 2026/4
N2 - Objectives: The effects of risk-reducing salpingo-oophorectomy on the development of cardiovascular risk factors in women with BRCA1/2 pathogenic variants are unknown. We compared the development of cardiovascular risk factors 5 years post-surgery between participants who had risk-reducing salpingo-oophorectomy with and without hormonal replacement therapy and participants who had risk-reducing salpingectomy. Study design: Eligible participants with a BRCA1/2 pathogenic variant from the TUBA study were longitudinally followed and categorized into three groups: (1) salpingectomy without subsequent oophorectomy within 5 years, (2) salpingo-oophorectomy with hormonal replacement therapy (use ≥3 years), (3) salpingo-oophorectomy without hormonal replacement therapy (use <3 years). Main outcome measures: Development of cardiovascular risk factors between baseline and 5 years after salpingo-oophorectomy or salpingectomy. Results: Of the 400 participants, 258 (64.5%) had salpingectomy, 93 (23.3%) had salpingo-oophorectomy and used hormonal replacement therapy ≥3 years, and 49 (12.2%) used it for <3 years. At 5-year follow-up, the cardiovascular risk factor hypercholesterolemia (increased LDLc) was observed more often after salpingo-oophorectomy with (18.8%, p ≤0.001) and without (17.1%, p = 0.03) hormonal replacement therapy compared with the salpingectomy group (5.7%). Larger proportions of participants after salpingo-oophorectomy with (47.1%) and without (50.0%) hormonal replacement therapy experienced an increase in the number of risk factors present compared with participants after salpingectomy (24.5%; p = 0.009, p = 0.02, respectively). Conclusions: Overall, only a small proportion of the study population developed cardiovascular risk factors within five years after salpingo-oophorectomy. However, participants developed the risk factor hypercholesterolemia more after salpingo-oophorectomy (irrespective of use of hormonal replacement therapy) compared with after salpingectomy.
AB - Objectives: The effects of risk-reducing salpingo-oophorectomy on the development of cardiovascular risk factors in women with BRCA1/2 pathogenic variants are unknown. We compared the development of cardiovascular risk factors 5 years post-surgery between participants who had risk-reducing salpingo-oophorectomy with and without hormonal replacement therapy and participants who had risk-reducing salpingectomy. Study design: Eligible participants with a BRCA1/2 pathogenic variant from the TUBA study were longitudinally followed and categorized into three groups: (1) salpingectomy without subsequent oophorectomy within 5 years, (2) salpingo-oophorectomy with hormonal replacement therapy (use ≥3 years), (3) salpingo-oophorectomy without hormonal replacement therapy (use <3 years). Main outcome measures: Development of cardiovascular risk factors between baseline and 5 years after salpingo-oophorectomy or salpingectomy. Results: Of the 400 participants, 258 (64.5%) had salpingectomy, 93 (23.3%) had salpingo-oophorectomy and used hormonal replacement therapy ≥3 years, and 49 (12.2%) used it for <3 years. At 5-year follow-up, the cardiovascular risk factor hypercholesterolemia (increased LDLc) was observed more often after salpingo-oophorectomy with (18.8%, p ≤0.001) and without (17.1%, p = 0.03) hormonal replacement therapy compared with the salpingectomy group (5.7%). Larger proportions of participants after salpingo-oophorectomy with (47.1%) and without (50.0%) hormonal replacement therapy experienced an increase in the number of risk factors present compared with participants after salpingectomy (24.5%; p = 0.009, p = 0.02, respectively). Conclusions: Overall, only a small proportion of the study population developed cardiovascular risk factors within five years after salpingo-oophorectomy. However, participants developed the risk factor hypercholesterolemia more after salpingo-oophorectomy (irrespective of use of hormonal replacement therapy) compared with after salpingectomy.
KW - BRCA1
KW - BRCA2
KW - Cardiovascular risk
KW - Hormonal replacement therapy
KW - Ovarian cancer
KW - Prevention
UR - https://www.scopus.com/pages/publications/105030486408
U2 - 10.1016/j.maturitas.2026.108886
DO - 10.1016/j.maturitas.2026.108886
M3 - Article
AN - SCOPUS:105030486408
SN - 0378-5122
VL - 207
JO - Maturitas
JF - Maturitas
M1 - 108886
ER -